A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Vijay Maruti PatilVanita NoronhaAmit JoshiJaiprakash AgarwalSarbani Ghosh LaskarAshwini BudrukkarVedang MurthyTejpal GuptaManoj MahimkarShashikant JuvekarSupreeta AryaAbhishek MahajanArchi AgarwalNilendu PurandareVenkatesh RangarajanArun BalajiSameer Vasant ChaudhariShripad BanavaliSadhana KannanAtanu BhattacharjeeAnil K D'CruzPankaj ChaturvediPrathamesh S PaiDevendra ChaukarGouri PantvaidyaDeepa NairSudhir NairAnuja DeshmukhShivakumar ThiagarajanVijayalakshmi MathrudevAparna ManjrekarSachin DhumalKamesh MaskeArti Sanjay BhelekarKavita NawaleArun ChandrasekharanNikhil PandeAlok GoelVikas TalrejaVijai SimhaSujay SrinivasRohit SwamiDilip Harindran VallatholHollis DsouzaSameer ShrirangwarSiddharth TurkarGeorge AbrahamAditi Harsh ThankyUsha PatelManish Kumar PandeyKumar PrabhashPublished in: Cancer (2019)
The addition of nimotuzumab to concurrent weekly CRT improves PFS, LRC, and DFS. This combination provides a novel alternative therapeutic option to a 3-weekly schedule of 100 mg/m2 cisplatin in patients with locally advanced head and neck cancer who are treated with radical-intent CRT.